Belgium-based Promethera Biosciences SA, which is developing cell-based treatments for in-born errors of metabolism and acquired liver disease, has raised €10 million in a Series C-extension financing to expand its portfolio. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals